Hayashi and colleagues (114) have reported dasatinib treatment markedly enhances NK cell cytotoxic function in CML patients and this is associated with an increased number of cells in the NK lineage, including CD3−CD56+ and mature CD56+CD57+ cells to levels not obtained with imatinib or nilotinib (115). This evidence concerns the gene B3GAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.